Despite the decision being a win for Novo Nordisk, the compounded drugs sector is far too complex for this to be a final resolution.

A US judge has rejected efforts by a compounded drugs industry group to keep making an alternative version of Novo Nordisk’s popular drug semaglutide, opening the door for the US Food and Drug ...